Background: The role of antiretroviral therapy (ART) for Hepatitis C viral load (HCV-VL) and liver fibrosis is poorly understood. This study aimed at evaluating the influence of ART on HCV-VL and liver fibrosis in human immunodeficiency virus (HIV)/HCV-coinfected patients. Methods: We conducted a retrospective cohort study of HIV/HCV-coinfected patients followed at a tertiary university hospital. Results: In total, 143 patients were included. In 61 patients, ART initiation was accompanied by an increase in HCV-VL and a decrease in HIV viral load (HIV-VL), whereas ART suspension led to a decrease in HCV-VL and an increase in HIV-VL. Among the 55 HIV-suppressed patients who switched to a raltegravir (RAL)-containing regimen, median HCV-VL levels decreased significantly, while switching to a rilpivirine-containing regimen did not yield a significant reduction. Discussion: If the ­treatment of chronic hepatitis starts before ART, ART initiation should be delayed as much as possible. If ART has been started, it is advisable to wait 1 year before initiating chronic hepatitis treatment. RAL as the third agent in an ART regimen could be beneficial in HIV/HCV-coinfected patients, in comparison to other antiretroviral drugs. Conclusion: The start and the suspension of ART significantly interferes with HCV-VL in HIV/HCV-coinfected patients.
Intervirology

中文翻译：

---

抗逆转录病毒疗法对人免疫缺陷病毒合并感染患者的丙型肝炎病毒载量和肝纤维化的影响：一项观察性研究。

背景：人们对抗逆转录病毒疗法（ART）在丙型肝炎病毒载量（HCV-VL）和肝纤维化中的作用了解甚少。这项研究旨在评估ART对人类免疫缺陷病毒（HIV）/ HCV合并感染患者的HCV-VL和肝纤维化的影响。方法：我们对三级大学医院中的HIV / HCV合并感染患者进行了回顾性队列研究。结果：总共包括143位患者。在61例患者中，ART开始伴随着HCV-VL的增加和HIV病毒载量（HIV-VL）的减少，而ART悬浮液导致HCV-VL的减少和HIV-VL的增加。在转为使用含有raltegravir（RAL）方案的55例HIV抑制患者中，中位HCV-VL水平显着下降，而改用含rilpivirine的方案并没有显着降低。讨论：如果慢性肝炎的治疗在抗逆转录病毒治疗之前开始，应尽可能推迟抗逆转录病毒治疗的开始时间。如果已开始抗逆转录病毒治疗，建议等待1年后再开始慢性肝炎治疗。与其他抗逆转录病毒药物相比，RAL作为ART方案中的第三种药物可能对HIV / HCV感染的患者有益。结论： ART的开始和停止显着干扰HIV / HCV合并感染患者的HCV-VL。
病毒学